ArticlePloS one2026
Quantitative analysis of free polyethylene glycols in PEGylated peptides using reverse-phase high-performance liquid chromatography and charged aerosol detection.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PEGylation is a well-established strategy used to enhance the pharmacokinetic and pharmacodynamic properties of peptide drugs. However, free polyethylene glycol (PEG) remains a critical process-related impurity. Conventional detection methods for nonchromophoric compounds such as PEG, which include the use of evaporative light scattering (ELS) and refractive index (RI) detectors, are limited by their low sensitivity and poor compatibility with the gradient elution. Herein, systematically optimized reverse-phase high-performance liquid chromatography (RP-HPLC) coupled with charged aerosol detection (CAD) was developed and validated for the quantification of free PEG in three representative PEGylated peptide therapeutics: PEG-loxenatide, pegmolesatide, and visepegenatide. The proposed method implements a co-optimization strategy for CAD parameters, with the power function value (PFV) applied during CAD signal acquisition and the power law(PL) setting adjusted during data processing.This dual optimization effectively linearizes the inherently nonlinear CAD response across a broad concentration range, enabling a linear relationship between PEG concentration and detector response. Method validation demonstrated satisfactory specificity, precision, linearity, accuracy, robustness, and solution stability in accordance with the applicable guidelines and pharmacopoeial requirements. Practical applicability was confirmed by analyzing multiple drug batches and accelerated stability samples.A Wilcoxon signed-rank test showed no statistically significant difference between the results obtained under the default and co-optimized settings (P > 0.05), indicating that the two settings produced comparable results under the conditions evaluated. The proposed HPLC-CAD method provides a practical analytical approach in the analysis of PEGylated peptide pharmaceuticals by achieving a linearized CAD response through PFV and PL co-optimization, providing an effective approach for free PEG quantification in routine quality control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.